3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
49
Rectal Neoplasms
29
Pancreatic Neoplasms
25
Colonic Neoplasms
25
Neoplasm Metastasis
19
Stomach Neoplasms
17
Neoplasms
17
Esophageal Neoplasms
17
Head and Neck Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Breast Neoplasms
10
Adenocarcinoma Of Esophagus
8
Esophageal Squamous Cell Carcinoma
6
Cholangiocarcinoma
6
Carcinoma, Squamous Cell
6
Gallbladder Neoplasms
5
Carcinoma, Hepatocellular
5
Bile Duct Neoplasms
5
Liver Neoplasms
4
Anus Neoplasms
4
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Somatostatinoma
2
Sarcoma
2
Peritoneal Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Interventions
umbralisib
1
ublituximab
1
marizomib
1
fludarabine phosphate
1
fludarabine
1
enzastaurin
1
durvalumab
1
carotuximab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
Zoledronic Acid
1
Vitamin D
1
Receptors, Interleukin-6
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Interleukin 1 Receptor Antagonist Protein
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cyclophosphamide
1
Cisplatin
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease Progression
×
Fluorouracil
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts